The stock is bouncing back from a recent 52-week low.
The company is poised to report a critical set of clinical data in the coming months.
Novavax (NVAX) is expected to provide updates on its ongoing clinical development in the first quarter of 2023.
Bellerophon (BLPH) is expected to provide updates on its proprietary INOpulse platform, being developed for treating several pulmonary hypertension indications, on its first-quarter earnings call.
A notable analyst upgrade had investors piling into this clinical-stage biotech stock today.
Allakos Inc. (ALLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Investors appear to be getting into position ahead of a major upcoming catalyst.
SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab...
SAN CARLOS, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab...
The Schall Law Firm, a national shareholder rights litigation firm, announces it is investigating potential breaches of fiduciary duties by the management of Allakos, Inc. (“Allakos”) (NASDAQ: ALLK...